In a significant development for rare disease treatment, the experimental drug navepegritide has demonstrated both safety and efficacy in a Phase 3 clinical trial for achondroplasia, according to researchers. The once-weekly treatment showed promising results in improving growth outcomes for patients with this genetic condition that causes dwarfism.
The study, led by Dr. Carlos Bacino and his team, involved over 200 pediatric patients across multiple international sites. Researchers reported statistically significant improvements in annualized growth velocity compared to placebo, with similar adverse event profiles between groups.
Achondroplasia affects approximately 1 in 15,000 to 40,000 newborns worldwide, making it the most common form of disproportionate short stature. Current treatment options are limited, with most approaches focusing on symptom management rather than addressing the underlying genetic cause.
“These results represent an important step forward,” said one researcher familiar with the trial who requested anonymity as full data hasn’t been published. “The convenience of weekly dosing could significantly improve quality of life for patients and families.”
Analysts suggest the drug could receive FDA approval within 12-18 months if further regulatory reviews confirm these findings. The manufacturer has already initiated discussions with global health authorities about potential fast-track designation.